Brivaracetam Disposition in Mild to Severe Hepatic Impairment
Author:
Affiliation:
1. UCB Pharma; Clinical Pharmacology; Braine-l'Alleud; Belgium
2. Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc; Université Catholique de Louvain; Brussels; Belgium
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.82/fullpdf
Reference29 articles.
1. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X);Bialer;Epilepsy Res.,2010
2. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity;Kenda;J Med Chem.,2004
3. Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture;Zona;Epilepsy Res.,2010
4. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A;Matagne;Br J Pharmacol.,2008
5. Protective effects of brivaracetam in phenytoin-resistant amygdala-kindled mice: a comparison with levetiracetam;Kaminski;Epilepsia.,2009
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Physiologically based pharmacokinetic model of brivaracetam to predict the exposure and dose exploration in hepatic impairment and elderly populations;Journal of Pharmaceutical Sciences;2024-09
2. Investigating clinical pharmacokinetics of brivaracetam by using a pharmacokinetic modeling approach;Scientific Reports;2024-06-11
3. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy;Advances in Therapy;2024-05-29
4. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil;Neuroscience Bulletin;2023-10-28
5. Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants;Clinical Pharmacology in Drug Development;2023-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3